Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

Bay Street

4 years ago

Pivotal NORSE 2 safety and efficacy data expected to be reported in the third calendar quarter of 2021
ONS-5010 / LYTENAVA™
Bay Street News